There is a greater need for dedicated clinical trials that focus specifically on RHF and PAH populations and which examine how PDE9A inhibition interacts with standard-of-care treatments such as PDE5 inhibitors and neprilysin inhibitors, and not just simply assess structural and functional improvements. Here, PDE9A is linked to pulmonary arterial hypertension.